RAPT Therapeutics, Inc. (RAPT) Enterprise Value (2020 - 2024)
RAPT Therapeutics' Enterprise Value history spans 5 years, with the latest figure at -$97.8 million for Q3 2024.
- For Q3 2024, Enterprise Value rose 47.08% year-over-year to -$97.8 million; the TTM value through Sep 2024 reached -$97.8 million, up 47.08%, while the annual FY2023 figure was -$158.9 million, 36.22% up from the prior year.
- Enterprise Value for Q3 2024 was -$97.8 million at RAPT Therapeutics, up from -$114.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$97.8 million in Q3 2024 and bottomed at -$249.1 million in Q4 2022.
- The 5-year median for Enterprise Value is -$173.0 million (2022), against an average of -$167.7 million.
- The largest annual shift saw Enterprise Value tumbled 75.81% in 2022 before it skyrocketed 47.08% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$111.5 million in 2020, then plummeted by 70.08% to -$189.7 million in 2021, then crashed by 31.33% to -$249.1 million in 2022, then soared by 36.22% to -$158.9 million in 2023, then soared by 38.45% to -$97.8 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's Enterprise Value are -$97.8 million (Q3 2024), -$114.8 million (Q2 2024), and -$141.6 million (Q1 2024).